Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Motor Activity 1Advanced Solid Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × mitazalimab × Clear all
NCT04888312 2025-10-08

OPTIMIZE-1

Alligator Bioscience AB

Phase 1/2 Active not recruiting
94 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02829099 2022-10-06

A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

Janssen Research & Development, LLC

Phase 1 Completed
95 enrolled

Advanced Solid Neoplasms

NCT02379741 2017-03-27

ADC-1013 First-in-Human Study

Alligator Bioscience AB

Phase 1 Completed
24 enrolled

Motor Activity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡